RESUMEN
Encapsulating peritoneal sclerosis (EPS) is a potentially devastating complication of peritoneal dialysis (PD). Diagnosis is often delayed due to the lack of effective and accurate diagnostic tools. We therefore examined peritoneal effluent for potential biomarkers that could predict or confirm the diagnosis of EPS and would be valuable in stratifying at-risk patients and driving appropriate interventions. Using prospectively collected samples from the Global Fluid Study and a cohort of Greek PD patients, we utilized 2D SDSPAGE/ MS and iTRAQ to identify changes in the peritoneal effluent proteome from patients diagnosed with EPS and controls matched for treatment exposure. We employed a combinatorial peptide ligand library to compress the dynamic range of protein concentrations to aid identification of low-abundance proteins. In patients with stable membrane function, fibrinogen γ-chain and heparan sulphate proteoglycan core protein progressively increased over time on PD. In patients who developed EPS, collagen-α1(I), γ-actin and Complement factors B and I were elevated up to five years prior to diagnosis. Orosomucoid-1 and a2-HS-glycoprotein chain-B were elevated about one year before diagnosis, while apolipoprotein A-IV and α1-antitrypsin were decreased compared to controls. Dynamic range compression resulted in an increased number of proteins detected with improved resolution of protein spots, compared to the full fluid proteome. Intelectin-1, dermatopontin, gelsolin, and retinol binding protein-4 were elevated in proteome-mined samples from patients with EPS compared to patients that had just commenced peritoneal dialysis. Thus, prospective analysis of peritoneal effluent uncovered proteins indicative of inflammatory and pro-fibrotic injury worthy of further evaluation as diagnostic/prognostic markers.
Asunto(s)
Soluciones para Diálisis/química , Fallo Renal Crónico/terapia , Diálisis Peritoneal/efectos adversos , Fibrosis Peritoneal/diagnóstico , Peritoneo/patología , Proteómica/métodos , Adulto , Anciano , Biomarcadores/análisis , Electroforesis en Gel de Poliacrilamida , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fibrosis Peritoneal/etiología , Pronóstico , Estudios Prospectivos , Proteoma/análisis , Medición de Riesgo/métodosRESUMEN
Renal oncocytomas are benign tumors of the kidneys, which are usually diagnosed postoperatively, due to differential diagnostic problems, from a sample of a renal cell carcinoma. The development of a renal oncocytoma in the native kidneys following renal transplantation is a very rare condition and only a few cases have been published in the world literature. In this case report we present a unique case of bilateral multifocal renal oncocytomas of the native kidneys in a female transplant recipient 6 years after renal transplantation. The patient's postoperative clinical course was uneventful and no local recurrence or distant metastasis has been found so far. The pathology, clinical characteristics, and treatment of renal oncocytomas are also reviewed.
Asunto(s)
Adenoma Oxifílico/etiología , Carcinoma de Células Renales/etiología , Fallo Renal Crónico/complicaciones , Neoplasias Renales/etiología , Trasplante de Riñón/efectos adversos , Complicaciones Posoperatorias , Adenoma Oxifílico/diagnóstico , Anciano , Carcinoma de Células Renales/diagnóstico , Femenino , Humanos , Fallo Renal Crónico/cirugía , Neoplasias Renales/diagnóstico , Imagen por Resonancia Magnética , Pronóstico , Literatura de Revisión como AsuntoRESUMEN
OBJECTIVES: Persistent secondary hyperparathyroidism is common after successful kidney transplant, with concomitant hypercalcemia and hypophosphatemia potentially leading to reduced graft survival and increased cardiovascular risk. Cinacalcet, a calcimimetic agent that activates the calcium-sensing receptors in parathyroid glands, is a therapeutic option. In this study, we assessed the long-term treatment effects of cinacalcet for a period of up to 5 years in a cohort of kidney transplant recipients. MATERIALS AND METHODS: Forty-seven patients with secondary hyperparathyroidism (intact parathyroid hormone level > 70 pg/mL or 7.43 pmol/L) and hypercalcemia (corrected calcium > 10.4 mg/dL or 2.6 mmol/L) were considered eligible for treatment with cinacalcet and were included in the analysis. Data were recorded at initiation of treatment and every 6 months up to a maximum follow-up of 60 months. A control group of patients treated with placebo, conventional treatment, or surgical treatment was not available for this study. RESULTS: Mean follow-up time was 45 ± 16 months. Treatment with cinacalcet was initiated at a median of 25 months after renal transplant. Serum calcium decreased by 0.21 mmol/L (2.69 vs 2.48 mmol/L; 95% confidence interval, 0.08-0.345; P < .001) during the first 6 months, and this reduction was sustained during follow-up. Intact parathyroid hormone level decreased by 7.68 pmol/L (32.96 ± 36.4 vs 25.28 ± 19.5 pmol/L; 95% confidence interval, -6.42 to 21.75; P = not significant) at 6 months, whereas at the end of follow-up intact parathyroid hormone level decreased further by 20.07 pmol/L (32.96 ± 36.4 vs 12.89 ± 5.73 pmol/L; 95% confidence interval, 2.02-38.1; P < .01). Mean starting dose of cinacalcet was 33.5 ± 10 mg/day. According to the therapeutic response, cinacalcet dose increased steadily and reached 51.1 ± 33 mg/day at the end of the observation period. Mean serum phosphorus increased significantly, whereas estimated glomerular filtration rate remained virtually stable throughout follow-up. Adverse reactions were observed in 4 patients, comprising mild gastro-intestinal complaints. CONCLUSIONS: Long-term treatment with cinacalcet in kidney transplant recipients with secondary hyperparathyroidism is effective in controlling hypercalcemia and correcting hypophosphatemia, without affecting graft function while being well-tolerated.
Asunto(s)
Calcimiméticos/administración & dosificación , Calcio/sangre , Cinacalcet/administración & dosificación , Hipercalcemia/tratamiento farmacológico , Hiperparatiroidismo Secundario/tratamiento farmacológico , Fallo Renal Crónico/cirugía , Trasplante de Riñón , Adulto , Biomarcadores/sangre , Calcimiméticos/efectos adversos , Cinacalcet/efectos adversos , Esquema de Medicación , Femenino , Grecia , Humanos , Hipercalcemia/sangre , Hipercalcemia/diagnóstico , Hipercalcemia/etiología , Hiperparatiroidismo Secundario/sangre , Hiperparatiroidismo Secundario/diagnóstico , Hiperparatiroidismo Secundario/etiología , Hipofosfatemia/sangre , Hipofosfatemia/tratamiento farmacológico , Hipofosfatemia/etiología , Fallo Renal Crónico/complicaciones , Fallo Renal Crónico/diagnóstico , Trasplante de Riñón/efectos adversos , Masculino , Persona de Mediana Edad , Hormona Paratiroidea/sangre , Fosfatos/sangre , Estudios Prospectivos , Factores de Tiempo , Resultado del TratamientoRESUMEN
OBJECTIVES: We report the incidence and pattern of malignancies in renal transplant recipients from our department. MATERIALS AND METHODS: Between March 1983 and August 2013, the records of 2054 renal transplant recipients from our department were retrospectively reviewed with regard to type of neoplasm, age, gender, interval between the transplant and the diagnosis of malignancy, immunosuppressive regimens, graft functional status, and rejection episodes. RESULTS: Among the 2054 renal transplant recipients, visceral malignancies developed in 74 patients (3.6%). The mean age at transplant was 43.9 years, and the mean age at death was 61.9 years. Sixty-eight patients (91.9%) died with a functioning graft. Fifty-four (73%) died during follow-up. The mean time from transplant to malignancy was 96.4 months, and from malignancy to death was 27.5 months. No difference regarding the type of immunosuppression, the type of donor, or the interval between transplant and malignancy was detected when we compared cancers. CONCLUSIONS: Malignancies after a renal transplant display aggressive behavior and occur more frequently several years after the transplant, but they also may occur earlier. The type of immunosuppression, the type of donor, or the interval between transplant and malignancy do not differ significantly among cancers.